Insilico Medicine published a Nature Communications paper describing D16‑M1P2, an AI‑designed PROTAC that targets PKMYT1 and showed preclinical activity in CCNE1‑amplified and FBXW7‑mutant tumor models. The company used its Chemistry42 generative platform to design the bifunctional degrader and linked biological dependency signals to potential biomarker‑guided clinical strategies. Separately, NeurIPS 2025 showcased the acceleration of foundation and generative models for biology, with companies and academic groups demonstrating improved protein‑ligand cofolding and virtual cell modeling. Organizers and participants emphasized that specialized AI models are moving drug discovery timelines and enabling new modalities such as AI‑driven degraders. The two developments illustrate the practical outputs of ML platforms: actionable chemical matter entering preclinical pipelines and community benchmarks at major AI conferences that validate technique transfer into therapeutics.